Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Griesinger

Showing results (271-280 of 298) with videos related to

Pageof 30
Sort By:
Journal of Medicinal Chemistry|December 27, 2021
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic TargetMyeongkyu Kim, Jung-Hye Ha, Joonhyeok Choi, et al.
Inorganic Chemistry|October 23, 2010
Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synucleinAndrés Binolfi, Esaú E Rodriguez, Daniela Valensin, et al.
Marine Drugs|May 27, 2022
Antimicrobial Diterpene Alkaloids from an <i>Agelas citrina</i> Sponge Collected in the Yucatán PeninsulaDawrin Pech-Puch, Abel M Forero, Juan Carlos Fuentes-Monteverde, et al.
Methods (San Diego, Calif.)|April 10, 2023
Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMRRıza Dervişoğlu, Leif Antonschmidt, Evgeny Nimerovsky, et al.
Nature Communications|September 14, 2022
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrilsLeif Antonschmidt, Dirk Matthes, Rıza Dervişoğlu, et al.
Nature Communications|July 1, 2022
A litmus test for classifying recognition mechanisms of transiently binding proteinsKalyan S Chakrabarti, Simon Olsson, Supriya Pratihar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2020
[<sup>11</sup>C]MODAG-001-towards a PET tracer targeting α-synuclein aggregatesLaura Kuebler, Sabrina Buss, Andrei Leonov, et al.
Ebiomedicine|May 2, 2022
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJohannes Levin, Nand Sing, Sue Melbourne, et al.
Nature Communications|January 17, 2025
Lipidic folding pathway of α-Synuclein via a toxic oligomerVrinda Sant, Dirk Matthes, Hisham Mazal, et al.
Nature Communications|October 3, 2025
Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formationMookyoung Han, Benedikt Frieg, Dirk Matthes, et al.
Pageof 30

Showing results (271-280 of 298) with videos related to

Sort By:
Pageof 30
Journal of Medicinal Chemistry|December 27, 2021
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic TargetMyeongkyu Kim, Jung-Hye Ha, Joonhyeok Choi, et al.
Inorganic Chemistry|October 23, 2010
Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synucleinAndrés Binolfi, Esaú E Rodriguez, Daniela Valensin, et al.
Marine Drugs|May 27, 2022
Antimicrobial Diterpene Alkaloids from an <i>Agelas citrina</i> Sponge Collected in the Yucatán PeninsulaDawrin Pech-Puch, Abel M Forero, Juan Carlos Fuentes-Monteverde, et al.
Methods (San Diego, Calif.)|April 10, 2023
Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMRRıza Dervişoğlu, Leif Antonschmidt, Evgeny Nimerovsky, et al.
Nature Communications|September 14, 2022
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrilsLeif Antonschmidt, Dirk Matthes, Rıza Dervişoğlu, et al.
Nature Communications|July 1, 2022
A litmus test for classifying recognition mechanisms of transiently binding proteinsKalyan S Chakrabarti, Simon Olsson, Supriya Pratihar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2020
[<sup>11</sup>C]MODAG-001-towards a PET tracer targeting α-synuclein aggregatesLaura Kuebler, Sabrina Buss, Andrei Leonov, et al.
Ebiomedicine|May 2, 2022
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJohannes Levin, Nand Sing, Sue Melbourne, et al.
Nature Communications|January 17, 2025
Lipidic folding pathway of α-Synuclein via a toxic oligomerVrinda Sant, Dirk Matthes, Hisham Mazal, et al.
Nature Communications|October 3, 2025
Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formationMookyoung Han, Benedikt Frieg, Dirk Matthes, et al.
Pageof 30